Serum chromogranin  A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin‐like cell hyperplasia and autoimmune gastritis

ConclusionsThe early detection and follow up of the later progression of enterochromaffin ‐like cell hyperplasia and autoimmune gastritis into gastric neuroendocrine tumors, which have ~100‐fold greater incidence in type 1 diabetes patients, can be achieved by assessment of CgA levels. Therefore, the use of CgA could be considered as a novel auxiliary biomarker in the care of these type 1 diabetes complications.

Source: Journal of Diabetes Investigation - February 4, 2020 Category: Endocrinology Authors: Zoltan Herold, Magdolna Herold, Peter Nagy, Attila Patocs, Marton Doleschall, Aniko Somogyi Tags: Original Article Source Type: research